Ramesh Kumar - 06 Oct 2022 Form 4 Insider Report for Ocugen, Inc. (OCGN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 Oct 2022, 16:06:48 UTC
Prior SEC filing
20 Jul 2022
Next SEC filing
09 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ramesh Kumar by Jessica Crespo, his attorney-in-fact

Key filing fact

Ramesh Kumar filed Form 4 for Ocugen, Inc. (OCGN) on 07 Oct 2022.

Key facts

  • This page summarizes Ramesh Kumar's Form 4 filing for Ocugen, Inc. (OCGN).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 07 Oct 2022, 16:06.

Change

  • Previous filing in this sequence was filed on 20 Jul 2022.
  • Current net transaction value: -$5,940.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCGN transaction

Common Stock

Options Exercise

Transaction value
$2,295
Shares
+4,500
Change %
Price
$0.5100
Shares after
4,500
Date
06 Oct 2022
Ownership
Direct
OCGN transaction

Common Stock

Sale

Transaction value
$8,235
Shares
-4,500
Change %
-100%
Price
$1.83
Shares after
0
Date
06 Oct 2022
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCGN transaction Derivative

Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-4,500
Change %
-50%
Price
$0.000000
Shares after
4,500
Date
06 Oct 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,500
Exercise price
$0.5100
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Footnote F2

The options, initially representing a right to purchase 54,000 shares, vest and become exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with Ocugen, Inc. on the applicable vesting dates.

SEC remarks

Exhibit List: Exhibit 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .